Skip to main content

Table 3 Logistic regression model identifying factors for distant recurrence agreement between TACT and routine datasets

From: Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository

 

Odds ratio

95% CI

P value

Year relapse reported

0.88

0.80, 0.97

0.01

Distant relapse site = lung

0.61

0.38, 0.98

0.04

Distant relapse site = brain

2.96

1.29, 6.77

0.01

Centre [A]

0.28

0.07, 1.09

0.07

Centre [B]

0.41

0.06, 2.98

0.38

Centre [C]

1.31

0.19, 8.83

0.78

Centre [D]

0.18

0.03, 0.99

0.05

Centre [E]

0.29

0.05, 1.58

0.15

Centre [F]

0.30

0.06, 1.45

0.14

Centre [G]

0.34

0.06, 1.83

0.21

Centre [H]

0.04

0.01, 0.23

< 0.001

Centre [I]

0.05

0.01, 0.29

0.001

Centre [J]

0.07

0.02, 0.33

0.001

Centre [K]

0.28

0.05, 1.52

0.14

Centre [L]

0.31

0.05, 1.92

0.21

Centre [M]

0.37

0.06, 2.29

0.29

Centre [N]

0.37

0.09, 1.61

0.19

Centre [O]

0.07

0.01, 0.43

0.004

Centre [P]

0.23

0.05, 1.19

0.08

Centre [Q]

0.66

0.09, 4.60

0.68

Centre [R]

0.06

0.01, 0.37

0.002

Centre [S]

0.14

0.03, 0.58

0.007

Centre [T]

0.19

0.04, 0.84

0.03

Centre [U]

0.11

0.02, 0.60

0.01

Centre [V]

0.08

0.02, 0.39

0.002

Centre [W]

0.15

0.04, 0.60

0.007

Centre [X]

0.07

0.01, 0.38

0.002

Centre [Y]

0.10

0.02, 0.50

0.005

  1. OR < 1 imply distant recurrence less likely to be identified in NCDR dataset compared to gold standard TACT dataset. Individual centres included in the model have been anonymised. TACT Taxotere and Adjuvant ChemoTherapy
Back to article page

Trials

ISSN: 1745-6215